X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SHASUN PHARMA with Biocon Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs BIOCON LTD - Comparison Results

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA BIOCON LTD SHASUN PHARMA/
BIOCON LTD
 
P/E (TTM) x 123.9 82.9 149.5% View Chart
P/BV x 8.5 7.8 109.4% View Chart
Dividend Yield % 0.2 0.2 146.7%  

Financials

 SHASUN PHARMA   BIOCON LTD
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
BIOCON LTD
Mar-17
SHASUN PHARMA/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs941,162 8.1%   
Low Rs46483 9.5%   
Sales per share (Unadj.) Rs214.2194.6 110.1%  
Earnings per share (Unadj.) Rs5.334.4 15.5%  
Cash flow per share (Unadj.) Rs15.848.3 32.8%  
Dividends per share (Unadj.) Rs1.001.00 100.0%  
Dividend yield (eoy) %1.40.1 1,176.3%  
Book value per share (Unadj.) Rs53.3241.9 22.1%  
Shares outstanding (eoy) m56.62200.00 28.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.34.2 7.7%   
Avg P/E ratio x13.123.9 54.8%  
P/CF ratio (eoy) x4.417.0 25.9%  
Price / Book Value ratio x1.33.4 38.6%  
Dividend payout %18.72.9 644.8%   
Avg Mkt Cap Rs m3,958164,440 2.4%   
No. of employees `000NA9.2 0.0%   
Total wages/salary Rs m2,1647,470 29.0%   
Avg. sales/employee Rs ThNM4,213.9-  
Avg. wages/employee Rs ThNM809.0-  
Avg. net profit/employee Rs ThNM745.2-  
INCOME DATA
Net Sales Rs m12,12738,911 31.2%  
Other income Rs m2291,571 14.6%   
Total revenues Rs m12,35640,482 30.5%   
Gross profit Rs m1,0099,795 10.3%  
Depreciation Rs m5942,772 21.4%   
Interest Rs m415260 159.7%   
Profit before tax Rs m2308,334 2.8%   
Minority Interest Rs m0163 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-731,616 -4.5%   
Profit after tax Rs m3026,881 4.4%  
Gross profit margin %8.325.2 33.1%  
Effective tax rate %-31.719.4 -163.3%   
Net profit margin %2.517.7 14.1%  
BALANCE SHEET DATA
Current assets Rs m6,88440,477 17.0%   
Current liabilities Rs m8,45616,783 50.4%   
Net working cap to sales %-13.060.9 -21.3%  
Current ratio x0.82.4 33.8%  
Inventory Days Days6260 103.4%  
Debtors Days Days10883 129.8%  
Net fixed assets Rs m4,97045,073 11.0%   
Share capital Rs m1131,000 11.3%   
"Free" reserves Rs m2,87547,377 6.1%   
Net worth Rs m3,02048,377 6.2%   
Long term debt Rs m1,81721,082 8.6%   
Total assets Rs m13,34793,942 14.2%  
Interest coverage x1.633.1 4.7%   
Debt to equity ratio x0.60.4 138.1%  
Sales to assets ratio x0.90.4 219.4%   
Return on assets %5.47.6 70.7%  
Return on equity %10.014.2 70.3%  
Return on capital %13.312.6 105.7%  
Exports to sales %46.40-   
Imports to sales %14.20-   
Exports (fob) Rs m5,622NA-   
Imports (cif) Rs m1,728NA-   
Fx inflow Rs m5,84312,988 45.0%   
Fx outflow Rs m2,1737,899 27.5%   
Net fx Rs m3,6695,089 72.1%   
CASH FLOW
From Operations Rs m3986,400 6.2%  
From Investments Rs m-1,635-4,985 32.8%  
From Financial Activity Rs m1,309-1,775 -73.7%  
Net Cashflow Rs m71-473 -15.1%  

Share Holding

Indian Promoters % 39.2 40.4 97.0%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 3.6 8.4 42.9%  
FIIs % 17.6 10.7 164.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 19.9 199.0%  
Shareholders   20,750 109,995 18.9%  
Pledged promoter(s) holding % 12.3 0.0 30,725.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   PLETHICO PHARMA  DIVIS LABORATORIES  FULFORD INDIA  WYETH LTD  NOVARTIS  

Compare SHASUN PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 8-QTR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS